Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
M. Reck (Grosshansdorf, Germany). New and anticipated therapeutic developments in management of non-small-cell lung cancer. Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer

Member's Comments

No comment yet.

Related content which might interest you: New and emerging targeted treatments in advanced lung cancer Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management Year: 2016 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Current challenges in the management of nonsmall cell lung cancer brain metastases Source: Eur Respir J, 55 (1) 1901686; 10.1183/13993003.01686-2019 Year: 2020 Innovative local therapies in lung cancer Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018 Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer Source: Eur Respir J 2013; 42: 1119-1133 Year: 2013 Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 Advances in target therapy in lung cancer Source: Eur Respir Rev 2015; 24: 23-29 Year: 2015 Advances in target therapy for lung cancer Source: International Congress 2014 – Ceremony for the ERS Romain Pauwels Research Award 2014 - Clinical Year in Review I Year: 2014 Towards personalized treatment in non-small-cell lung carcinoma Source: Virtual Congress 2020 – Management issues in thoracic oncology Year: 2020 Immunology-based therapeutic strategies in lung cancer and mesothelioma Source: International Congress 2014 – Beyond tyrosine kinase inhibition: promising new developments in molecular oncology Year: 2014 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Current place and future of immunotherapy in lung cancer Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016 Milestones in the management of lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Possibilities of palliative combined therapy for extensive nonsmall cells lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 378s Year: 2001 Management of patients with non-small-cell lung cancer Source: ERS Live 2007 Year: 2007 Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019 Year: 2020